Investment will support development of the PD-1/VEGF bispecific with sonesitatug vedotin and other AstraZeneca cancer medicines, including additional ADCs IN BRIEFKEY TAKEAWAYSFAQs AstraZeneca has completed its $2 billion equity investment in Summit Therapeutics, with the funding intended to accelerate development … Read the full press release
Posted in Healthcare, Investment, Pharma & Biotech, Science, United Kingdom
Tagged $2 billion investment, ADCs, antibody-drug conjugates, AstraZeneca, AstraZeneca and Summit advance ivonescimab combination programme following completion of $2 billion investment, AstraZeneca closes $2 billion Summit Therapeutics equity investment for ivonescimab ADC combinations, AstraZeneca completes Summit investment as companies progress ivonescimab clinical collaborations, AstraZeneca finalises $2 billion Summit Therapeutics investment to accelerate ivonescimab combination development, AstraZeneca PLC, breast cancer, Cambridge, cancer medicines, clinical collaboration, Completed AstraZeneca investment supports expanded ivonescimab combinations with cancer medicines, Daiichi Sankyo, datopotamab deruxtecan, Datroway, equity investment, ivonescimab, lung cancer, oncology, PD-1, Sone-Ve, sonesitatug vedotin, Summit Therapeutics, United Kingdom, VEGF
The collaboration is set to begin with a Phase III trial in first-line triple-negative breast cancer, with the partners sharing trial costs while retaining rights to their respective medicines. IN BRIEFKEY TAKEAWAYSFAQs AstraZeneca and Daiichi Sankyo have entered into a … Read the full press release
Posted in Healthcare, Pharma & Biotech, United Kingdom
Tagged ADC, antibody-drug conjugate, AstraZeneca, AstraZeneca and Daiichi Sankyo expand ADC combination strategy with Summit’s ivonescimab, AstraZeneca, Daiichi Sankyo and Summit plan Datroway–ivonescimab clinical programme across multiple cancers, breast cancer, Daiichi Sankyo, datopotamab deruxtecan, Datroway, Datroway and ivonescimab combination to enter Phase III study under new AstraZeneca, Daiichi Sankyo and Summit collaboration, Dr. Maky Zanganeh, DXd ADC Technology, EGFR, ivonescimab, John Tsai, lung cancer, New clinical collaboration will test Datroway with ivonescimab in lung, breast and other tumour types, non-small cell lung cancer, NSCLC, PD-1, Phase III, Sone-Ve, sonesitatug vedotin, Summit Therapeutics, Susan Galbraith, TNBC, triple-negative breast cancer, TROP2, TROPION-Breast01, TROPION-Breast02, TROPION-Lung01, TROPION-Lung05, VEGF
NOTTINGHAM, 09-Mar-2017 — /EuropaWire/ — Scientists have discovered for the first time how animals link the change in seasons to their fertility. A study, led by academics at the Universities of Nottingham and Bristol and published in the journal Proceedings of … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?